Global Nanotechnology in Drug Delivery Market: Current Analysis and Forecast (2020-2027)

Table of Content

1 MARKET INTRODUCTION
1.1 Market Definitions
1.2 Objective of the Study
1.3 Limitation
1.4 Stake Holders
1.5 Currency Used in Report
1.6 Scope of the Global Nanotechnology in Drug Delivery Market Study

2 RESEARCH METHODOLOGY OR ASSUMPTION
2.1 Research Methodology for the Global Nanotechnology in Drug Delivery Market
2.1.1 Main Objective of the Global Nanotechnology in Drug Delivery Market

3 INDUSTRY PERFORMANCE

4 EXECUTIVE SUMMARY

5 FEW TOP START-UPS UNDER NANOTECHNOLOGY IN DRUG DELIVERY SECTOR

6 NANOTECHNOLOGY IN DRUG DELIVERY AMID COVID-19

7 GLOBAL NANOTECHNOLOGY IN DRUG DELIVERY MARKET BY REVENUE

8 MARKET INSIGHTS BY TECHNOLOGY
8.1 Nanoparticles
8.2 Liposomes
8.3 Nanocrystals
8.4 Micelles
8.5 Others

9 MARKET INSIGHTS BY APPLICATION
9.1 Oncology
9.2 Cardiovascular/Physiology
9.3 Anti-inflammatory/Immunology
9.4 Neurology
9.5 Anti-infective
9.6 Others

10 MARKET INSIGHTS BY REGION
10.1 North America Nanotechnology in Drug Delivery Market
10.1.1 United States
10.1.2 Canada
10.1.3 Rest of North America
10.2 Europe Nanotechnology in Drug Delivery Market
10.2.1 Germany
10.2.2 France
10.2.3 United Kingdom
10.2.4 Italy
10.2.5 Spain
10.2.6 Rest of Europe
10.3 Asia-Pacific Nanotechnology in Drug Delivery Market
10.3.1 China
10.3.2 Japan
10.3.3 South Korea
10.3.4 Australia
10.3.5 India
10.3.6 Rest of Asia Pacific
10.4 Rest of the World Nanotechnology in Drug Delivery Market

11 NANOTECHNOLOGY IN DRUG DELIVERY MARKET DYNAMICS
11.1 Market Drivers
11.2 Market Challenges
11.3 Impact Analysis

12 LEGAL & REGULATORY FRAMEWORK

13 DEMAND AND SUPPLY SIDE ANALYSIS
13.1 Demand Side Analysis
13.2 Supply Side Analysis
13.2.1 Top Product Launches
13.2.2 Top Business Partnerships
13.2.3 Top Merger & Acquisitions

14 VALUE CHAIN ANALYSIS

15 NANOTECHNOLOGY IN DRUG DELIVERY MARKET OPPORTUNITIES

16 NANOTECHNOLOGY IN DRUG DELIVERY MARKET TRENDS

17 COMPETITIVE SCENARIO
17.1 Porter’s Five Forces Analysis
17.1.1 Bargaining power of Supplier
17.1.2 Bargaining power of Buyer
17.1.3 Industry Rivalry
17.1.4 Availability of Substitute
17.1.5 Threat of new Entrants
17.2 Competitive Landscape
17.2.1 Company Shares, By Revenue

18 COMPANY PROFILED
18.1 Camarus AB
18.1.1 Key Facts
18.1.2 Ownership Structure
18.1.3 Business Description
18.1.4 Key Product/Services Offerings
18.1.5 Growth Strategy
18.1.6 SWOT Analysis
18.1.7 Key Financials
18.1.7.1 Revenue Split
18.1.7.2 Financial Overview of Camarus AB
18.1.8 Recent Developments
18.1.8.1 Product Launches
18.2 Taiwan Liposome Co
18.3 Novartis
18.4 Nanobiotix
18.5 NanoCarrier Co, LTD
18.6 Bayer
18.7 Selecta Biosciences
18.8 Pfizer
18.9 Starpharma Holdings Limited
18.10 Merck & Co

19 DISCLAIMER